8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Mar 31, 2026·SEC
Material company update
Jan 7, 2026·SEC
Omeros Corporation(OMER)Earnings, Financials & Key Ratios
OMER•NASDAQ
Price updated Jun 19, 2026
AboutOmeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.Show more
- Revenue$0
- EBITDA-$122M+27.6%
- Net Income-$3M+97.9%
- EPS (Diluted)-0.05+98.0%
OMER Key Insights
Omeros Corporation (OMER) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 52.5%
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when OMER posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OMER Price & Volume
Omeros Corporation (OMER) stock price & volume — 10-year historical chart
Loading chart...
OMER Growth Metrics
Omeros Corporation (OMER) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM156.29%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM149.06%
Return on Capital
10 Years-84.17%
5 Years-53.95%
3 Years-54.06%
Last Year-55.17%
OMER Recent Earnings
Omeros Corporation (OMER) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 1/12 qtrs (100%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.24+40.0%
$0.40
Rev
$10M+136.4%
$4M
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$3.14+670.9%
$0.55
Rev
—
$2M
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.19+67.2%
$0.58
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.53+3.6%
$0.55
Rev
—
$312,500
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.24vs $0.40+40.0% | $10Mvs $4M+136.4% |
| Q2 2026 | Mar 31, 2026 | $3.14vs $0.55+670.9% | —vs $2M |
| Q4 2025 | Nov 13, 2025 | $0.19vs $0.58+67.2% | — |
| Q3 2025 | Aug 14, 2025 | $0.53vs $0.55+3.6% | —vs $312,500 |
Based on last 12 quarters of dataView full earnings history →
OMER Peer Comparison
Omeros Corporation (OMER) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PTCT | 6.55B | 78.98 | 10.15 | 114.51% | -22.58% | |||
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 PRTA | 467.51M | 8.93 | -1.97 | -92.84% | -260.92% | -49.88% | 0.05 | |
 BCAB | 4.61M | 3.66 | -0.07 | -81.82% | -25.31% | |||
 APLS | 5.25B | 41.03 | 227.94 | 28.46% | 12.95% | 39.71% | 1.31 |
Compare OMER vs Peers
Omeros Corporation (OMER) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OMER Income Statement
Omeros Corporation (OMER) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 64.83M | 29.87M | 111.81M | 0 | 0 | 0 | 0 | 0 | 0 | 9.89M |
Revenue Growth % | 55.77% | -53.93% | 274.33% | -100% | - | - | - | - | - | - |
Cost of Goods Sold | 1.08M | 512K | 2.65M | 1.62M | 1.39M | 0 | 0 | 0 | 0 | 11.12M |
COGS % of Revenue | 1.66% | 1.71% | 2.37% | - | - | - | - | - | - | - |
Gross Profit | 63.75M▲ 0% | 29.36M▼ 53.9% | 109.15M▲ 271.8% | -1.62M▼ 101.5% | -1.39M▲ 14.2% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -1.23M▲ 0% |
Gross Margin % | 98.34% | 98.29% | 97.63% | - | - | - | - | - | - | -12.39% |
Gross Profit Growth % | 58.56% | -53.95% | 271.81% | -101.48% | 14.23% | 100% | - | - | - | - |
Operating Expenses | 107.64M | 141.58M | 172.53M | 155.3M | 172.23M | 163.39M | 164.53M | 169.26M | 122.8M | 104.02M |
OpEx % of Revenue | 166.05% | 474.01% | 154.32% | - | - | - | - | - | - | - |
Selling, General & Admin | 52.04M | 51.72M | 62.84M | 47.69M | 53.46M | 50.67M | 49.66M | 49.73M | 41.5M | 33.4M |
SG&A % of Revenue | 80.28% | 173.16% | 56.2% | - | - | - | - | - | - | - |
Research & Development | 55.6M | 89.86M | 109.7M | 107.61M | 118.78M | 112.72M | 114.87M | 119.52M | 81.3M | 70.57M |
R&D % of Revenue | 85.77% | 300.86% | 98.11% | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 52K |
Operating Income | -43.9M▲ 0% | -112.22M▼ 155.7% | -63.38M▲ 43.5% | -156.92M▼ 147.6% | -173.62M▼ 10.6% | -163.39M▲ 5.9% | -164.53M▼ 0.7% | -169.26M▼ 2.9% | -122.8M▲ 27.5% | -105.25M▲ 0% |
Operating Margin % | -67.71% | -375.73% | -56.69% | - | - | - | - | - | - | -1063.86% |
Operating Income Growth % | 19.13% | -155.66% | 43.52% | -147.57% | -10.64% | 5.89% | -0.7% | -2.87% | 27.45% | - |
EBITDA | -43.34M | -111.26M | -61.59M | -155.3M | -172.23M | -162.44M | -163.61M | -168.31M | -121.83M | -104.33M |
EBITDA Margin % | -66.86% | -372.51% | -55.09% | - | - | - | - | - | - | -1054.62% |
EBITDA Growth % | 19.7% | -156.69% | 44.64% | -152.15% | -10.9% | 5.69% | -0.72% | -2.87% | 27.61% | 36.44% |
D&A (Non-Cash Add-back) | 551K | 962K | 1.79M | 1.62M | 1.39M | 952K | 920K | 950K | 964K | 914K |
EBIT | -42.45M | -123.43M | -61.83M | -169.64M | -171.88M | -159.33M | -144.08M | -157.95M | -122.8M | -105.25M |
Net Interest Income | -11.03M | -16.25M | -22.66M | -26.1M | -19.65M | -18.64M | -14.5M | -13.37M | 5.06M | 9.3M |
Interest Income | 0 | 0 | 0 | 654K | 17.93K | 4.06M | 0 | 11.3M | 5.06M | 15.21M |
Interest Expense | 11.03M | 16.25M | 22.66M | 26.75M | 19.67M | 22.7M | 14.5M | 24.68M | 0 | 5.91M |
Other Income/Expense | -9.59M | -27.46M | -21.1M | -39.47M | -17.93M | -18.64M | -10.39M | -13.37M | 120M | 191.32M |
Pretax Income | -53.48M▲ 0% | -139.69M▼ 161.2% | -84.49M▲ 39.5% | -196.39M▼ 132.5% | -191.55M▲ 2.5% | -182.03M▲ 5.0% | -174.92M▲ 3.9% | -182.63M▼ 4.4% | -2.8M▲ 98.5% | 86.08M▲ 0% |
Pretax Margin % | -82.5% | -467.68% | -75.57% | - | - | - | - | - | - | 870.07% |
Income Tax | 0 | -12.93M | 0 | -23.26M | 0 | 0 | 0 | 0 | 2.01M | 2.07M |
Effective Tax Rate % | 0% | 9.26% | 0% | 11.84% | 0% | 0% | 0% | 0% | -71.96% | 2.4% |
Net Income | -53.48M▲ 0% | -126.76M▼ 137.0% | -84.49M▲ 33.3% | -138.06M▼ 63.4% | -111.41M▲ 19.3% | 47.42M▲ 142.6% | -117.81M▼ 348.5% | -156.81M▼ 33.1% | -3.35M▲ 97.9% | 86.17M▲ 0% |
Net Margin % | -82.5% | -424.39% | -75.57% | - | - | - | - | - | - | 871.02% |
Net Income Growth % | 19.87% | -137.01% | 33.35% | -63.41% | 19.3% | 142.56% | -348.46% | -33.11% | 97.86% | 156.29% |
Net Income (Continuing) | -53.48M | -126.76M | -84.49M | -173.13M | -191.55M | -182.03M | -174.92M | -182.63M | -4.81M | 84.01M |
Discontinued Operations | 0 | 0 | 0 | 35.07M | 80.13M | 229.45M | 57.11M | 25.81M | 1.46M | 1.46M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.17▲ 0% | -2.61▼ 123.1% | -2.16▲ 17.2% | -2.41▼ 11.6% | 3.12▲ 229.5% | 0.46▼ 85.3% | -1.88▼ 508.7% | -2.70▼ 43.6% | -0.05▲ 98.0% | 1.36▲ 0% |
EPS Growth % | 29.09% | -123.08% | 17.24% | -11.57% | 229.46% | -85.26% | -508.7% | -43.62% | 98.05% | 149.06% |
EPS (Basic) | -1.17 | -2.61 | -2.16 | -2.41 | 3.12 | 0.46 | -1.88 | -2.70 | -0.05 | - |
Diluted Shares Outstanding | 45.54M | 48.58M | 49.52M | 57.18M | 62.34M | 62.74M | 62.74M | 58.17M | 63.51M | 63.51M |
Basic Shares Outstanding | 45.54M | 48.58M | 49.52M | 57.18M | 62.34M | 62.74M | 62.74M | 58.17M | 63.51M | 71.92M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
OMER Balance Sheet
Omeros Corporation (OMER) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 108.37M | 89.87M | 103.75M | 151.28M | 247.96M | 443.24M | 217.9M | 134.12M | 215.67M | 180.35M |
Cash & Short-Term Investments | 83.75M | 60.5M | 60.79M | 134.95M | 157.27M | 194.92M | 171.85M | 90.13M | 171.8M | 135.32M |
Cash Only | 3.39M | 5.86M | 3.08M | 10.5M | 100.81M | 11.01M | 7.11M | 3.4M | 9.66M | 1.91M |
Short-Term Investments | 80.36M | 54.64M | 57.7M | 124.45M | 56.46M | 183.91M | 164.74M | 86.73M | 162.14M | 133.41M |
Accounts Receivable | 17.14M | 22.82M | 35.19M | 3.84M | 82.47M | 242.02M | 6.72M | 36.82M | 36.27M | 37.51M |
Days Sales Outstanding | 96.53 | 278.85 | 114.87 | - | - | - | - | - | - | 1.29K |
Inventory | 443K | 52.51M | 1.15M | 1.35M | 0 | 0 | 0 | 0 | 0 | 183K |
Days Inventory Outstanding | 150 | 37.43K | 157.69 | 306.05 | - | - | - | - | - | 1.5 |
Other Current Assets | 0 | 6.46M | 6.63M | 681K | 67K | 6.3M | 30.75M | 7.17M | 7.59M | 7.35M |
Total Non-Current Assets | 7.96M | 6.07M | 33.22M | 29.76M | 171.31M | 147.73M | 160.37M | 142.96M | 109.97M | 105.82M |
Property, Plant & Equipment | 2.12M | 3.85M | 30.91M | 28.08M | 30.01M | 23.25M | 20.58M | 17.64M | 12.48M | 11.05M |
Fixed Asset Turnover | 30.56x | 7.77x | 3.62x | - | - | - | - | - | - | 0.75x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 5.83M | 1.15M | 1.15M | 0 | 0 | 0 | 0 | 0 | 0 | 94.77M |
Other Non-Current Assets | 0 | 1.07M | 1.16M | 1.68M | 141.31M | 124.48M | 139.79M | 125.32M | 97.49M | 0 |
Total Assets | 116.33M▲ 0% | 95.94M▼ 17.5% | 136.97M▲ 42.8% | 181.04M▲ 32.2% | 419.27M▲ 131.6% | 590.97M▲ 41.0% | 378.27M▼ 36.0% | 277.08M▼ 26.8% | 325.63M▲ 17.5% | 286.17M▲ 0% |
Asset Turnover | 0.56x | 0.31x | 0.82x | - | - | - | - | - | - | 0.04x |
Asset Growth % | 72.91% | -17.53% | 42.77% | 32.18% | 131.59% | 40.95% | -35.99% | -26.75% | 17.52% | -45.23% |
Total Current Liabilities | 26.31M | 37.36M | 55.46M | 36.74M | 51.79M | 136.38M | 53.32M | 79.53M | 78.06M | 59.44M |
Accounts Payable | 6.69M | 6.28M | 5.33M | 4.2M | 13.4M | 5.99M | 7.71M | 5.91M | 4.76M | 5.37M |
Days Payables Outstanding | 2.27K | 4.48K | 732.47 | 948.41 | 3.53K | - | - | - | - | 258.25 |
Short-Term Debt | 490K | 889K | 3.5M | 0 | 0 | 94.38M | 8.58M | 21M | 17.06M | 26.27M |
Deferred Revenue (Current) | -490K | -889K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.82M |
Other Current Liabilities | 16.46M | 26.58M | 43.08M | 3.95M | 3.71M | 7.82M | 0 | 29.51M | 48.79M | 14.1M |
Current Ratio | 4.12x | 2.41x | 1.87x | 4.12x | 4.79x | 3.25x | 4.09x | 1.69x | 2.76x | 3.03x |
Quick Ratio | 4.10x | 1.00x | 1.85x | 4.08x | 4.79x | 3.25x | 4.09x | 1.69x | 2.76x | 3.03x |
Cash Conversion Cycle | -2.02K | 33.24K | -459.92 | - | - | - | - | - | - | 1.04K |
Total Non-Current Liabilities | 92.83M | -41.58M | 190.53M | 265.06M | 343.7M | 368.9M | 349.94M | 380.16M | 368.8M | 290.06M |
Long-Term Debt | 83.31M | 148.98M | 158.21M | 236.29M | 313.46M | 220.91M | 329.7M | 166.58M | 208.53M | 278.76M |
Capital Lease Obligations | 810K | 1.58M | 32.32M | 28.77M | 29.13M | 22.43M | 18.14M | 13.47M | 7.25M | 32.07M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 8.72M | 8.18M | 0 | 0 | 1.11M | 125.57M | 2.09M | 200.11M | 153.02M | 5.7M |
Total Liabilities | 119.14M | -4.22M | 245.99M | 301.79M | 395.49M | 505.29M | 403.25M | 459.69M | 446.86M | 349.51M |
Total Debt | 84.61M | 151.45M | 194.03M | 268.84M | 347.84M | 342.02M | 361.58M | 207.02M | 239.14M | 310.63M |
Net Debt | 81.21M | 145.59M | 190.95M | 258.34M | 247.03M | 331.01M | 354.48M | 203.62M | 229.48M | 308.73M |
Debt / Equity | - | 0.23x | - | - | 14.63x | 3.99x | - | - | - | -4.90x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -2.98x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -2.96x |
Interest Coverage | -3.85x | -7.60x | -2.73x | -6.34x | -8.74x | -7.02x | -9.93x | -6.40x | - | -17.81x |
Total Equity | -2.81M▲ 0% | 650.13M▲ 23203.2% | -109.02M▼ 116.8% | -120.75M▼ 10.8% | 23.78M▲ 119.7% | 85.68M▲ 260.3% | -24.98M▼ 129.2% | -182.61M▼ 630.9% | -121.23M▲ 33.6% | -63.33M▲ 0% |
Equity Growth % | 92.49% | 23203.23% | -116.77% | -10.76% | 119.69% | 260.32% | -129.16% | -630.93% | 33.61% | -22.59% |
Book Value per Share | -0.06 | 13.38 | -2.20 | -2.11 | 0.38 | 1.37 | -0.40 | -3.14 | -1.91 | -1.00 |
Total Shareholders' Equity | -2.81M | 650.13M | -109.02M | -120.75M | 23.78M | 85.68M | -24.98M | -182.61M | -121.23M | -63.33M |
Common Stock | 482K | 490K | 542K | 616K | 626K | 628K | 611K | 580K | 716K | 720K |
Retained Earnings | -523.37M | 650.13M | -734.61M | -872.67M | -683.13M | -635.72M | -753.53M | -910.35M | -913.7M | -857.63M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -3.28M | -4.25M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OMER Cash Flow Statement
Omeros Corporation (OMER) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -36.23M | -103.74M | -60.07M | -100.09M | -109.72M | -86.48M | 74.73M | -148.8M | -116.09M | -94.76M |
Operating CF Margin % | -55.88% | -347.32% | -53.73% | - | - | - | - | - | - | - |
Operating CF Growth % | 29.66% | -186.35% | 42.09% | -66.61% | -9.63% | 21.18% | 186.41% | -299.13% | 21.98% | 116.72% |
Net Income | -53.48M | -126.76M | -84.49M | -138.06M | -191.55M | -182.03M | -117.81M | -156.81M | -3.35M | 86.17M |
Depreciation & Amortization | 551K | 962K | 1.79M | 1.62M | 1.39M | 952K | 920K | 950K | 964K | -1.32M |
Stock-Based Compensation | 12.69M | 11.71M | 13.79M | 14.93M | 0 | 0 | 11.65M | 10.49M | 8.19M | 5.74M |
Deferred Taxes | 0 | -12.93M | 0 | -12.01M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 4.19M | 18.98M | 9.23M | 25.86M | 94.54M | 213.56M | -67.45M | -33.17M | -155.62M | -217.51M |
Working Capital Changes | -172K | 4.29M | -394K | 7.58M | -14.11M | -118.97M | 247.42M | 29.74M | 33.72M | 36.97M |
Change in Receivables | -5.11M | -6.17M | -12.37M | 31.34M | -34.31M | -175.07M | 245.72M | 40.01M | 30.45M | 29.33M |
Change in Inventory | 685K | 355K | -1.06M | -208K | 0 | 0 | 0 | 0 | 0 | -183K |
Change in Payables | 9.52M | 10.54M | 13.28M | -19.74M | 14.64M | -10.66M | 0 | 0 | 0 | -979K |
Cash from Investing | -37.6M | 25.15M | -3.4M | -67.03M | 193.71M | -127.56M | 27.45M | 82.22M | 164.52M | 154.72M |
Capital Expenditures | -350K | -567K | -334K | -283K | -277K | -113K | -426K | -165K | -65K | 239.98M |
CapEx % of Revenue | 0.54% | 1.9% | 0.3% | - | - | - | - | - | - | 2425.72% |
Acquisitions | 0 | 0 | 3.07K | 0 | 125.99M | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -37.25K | 25.72K | -3.07K | 0 | 0 | 0 | 0 | 0 | 240M | 0 |
Cash from Financing | 75M | 81.05M | 60.7M | 174.53M | 6.32M | 124.25M | -106.08M | 62.88M | -42.17M | -62.31M |
Debt Issued (Net) | -431K | 109.62M | -1.14M | 98.2M | -1.82M | 123.83M | -101.58M | -41.34M | -89.16M | -109.19M |
Equity Issued (Net) | 63.66M | 0 | 54.24M | 93.67M | 8.38M | 415K | -4.65M | -11.85M | 46.99M | 50.74M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -4.65M | -11.85M | 0 | -4.15M |
Other Financing | 11.77M | -28.57M | 7.6M | -17.34M | -241K | 0 | 150K | 116.07M | 0 | -3.86M |
Net Change in Cash | 1.17M▲ 0% | 2.47M▲ 110.9% | -2.78M▼ 212.6% | 7.42M▲ 367.1% | 90.31M▲ 1117.6% | -89.8M▼ 199.4% | -3.9M▲ 95.7% | -3.71M▲ 5.1% | 6.26M▲ 269.0% | -2.35M▲ 0% |
Free Cash Flow | -36.58M▲ 0% | -104.3M▼ 185.2% | -60.41M▲ 42.1% | -100.37M▼ 66.2% | -110M▼ 9.6% | -86.6M▲ 21.3% | 74.3M▲ 185.8% | -148.97M▼ 300.5% | -116.16M▲ 22.0% | -94.78M▲ 0% |
FCF Margin % | -56.42% | -349.22% | -54.03% | - | - | - | - | - | - | -958.08% |
FCF Growth % | 29.16% | -185.16% | 42.09% | -66.15% | -9.59% | 21.28% | 185.8% | -300.5% | 22.02% | 33.72% |
FCF per Share | -0.80 | -2.15 | -1.22 | -1.76 | -1.76 | -1.38 | 1.18 | -2.56 | -1.83 | -1.49 |
FCF Conversion (FCF/Net Income) | 0.68x | 0.82x | 0.71x | 0.72x | 0.98x | -1.82x | -0.63x | 0.95x | 34.65x | -1.10x |
Interest Paid | 0 | 0 | 0 | 11.6M | 0 | 0 | 29.92M | 35.69M | 35.42M | 25.2M |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 3.29M | 165K | 153K | -29K |
OMER Key Ratios
Omeros Corporation (OMER) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -39.16% | -31.23% | - | -468.52% | 86.63% | -388.17% | - | - | -54.39% |
Return on Invested Capital (ROIC) | -55.59% | -19.26% | -10.83% | -107.22% | -63.77% | -35.65% | -33.07% | -72.43% | -142.5% | -114.35% |
Gross Margin | 98.34% | 98.29% | 97.63% | - | - | - | - | - | - | -12.39% |
Net Margin | -82.5% | -424.39% | -75.57% | - | - | - | - | - | - | 871.02% |
Debt / Equity | - | 0.23x | - | - | 14.63x | 3.99x | - | - | - | -4.90x |
Interest Coverage | -3.85x | -7.60x | -2.73x | -6.34x | -8.74x | -7.02x | -9.93x | -6.40x | - | -17.81x |
FCF Conversion | 0.68x | 0.82x | 0.71x | 0.72x | 0.98x | -1.82x | -0.63x | 0.95x | 34.65x | -1.10x |
Revenue Growth | 55.77% | -53.93% | 274.33% | -100% | - | - | - | - | - | - |
Related:OMER Dividend History·OMER Revenue History·OMER Price History·OMER P/E History·OMER Financial Ratios·OMER Institutional Holders
OMER SEC Filings & Documents
Omeros Corporation (OMER) SEC filings — annual & quarterly reports (10-K, 10-Q)
OMER Frequently Asked Questions
Omeros Corporation (OMER) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Omeros Corporation (OMER) reported $9.9M in revenue for fiscal year 2025. This represents a 414% increase from $1.9M in 2007.
Omeros Corporation (OMER) grew revenue by 0.0% over the past year. Growth has been modest.
Yes, Omeros Corporation (OMER) is profitable, generating $86.2M in net income for fiscal year 2025 (871.0% net margin).
Dividend & Returns
Omeros Corporation (OMER) had negative free cash flow of $94.8M in fiscal year 2025, likely due to heavy capital investments.